PMID- 34311543
OWN - NLM
STAT- MEDLINE
DCOM- 20210914
LR  - 20221207
IS  - 2093-5978 (Electronic)
IS  - 2093-596X (Print)
IS  - 2093-596X (Linking)
VI  - 36
IP  - 4
DP  - 2021 Aug
TI  - Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with 
      Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies.
PG  - 904-908
LID - 10.3803/EnM.2021.1048 [doi]
AB  - The coronavirus disease 2019 (COVID-19) pandemic remains an unbeaten enemy. 
      Unfortunately, no targeted treatment option is available. Patients with type 2 
      diabetes mellitus (T2DM) have increased odds for severe or fatal disease, as 
      demonstrated in recent observational studies. There is an ongoing discussion 
      regarding the impact of different antidiabetic drug classes on outcomes of 
      interest among affected subjects. Dipeptidyl peptidase-4 (DPP-4) inhibitors have 
      been placed at the epicenter, since the DPP-4 enzyme seems to be implicated in 
      the disease pathogenesis. Herein we present an updated meta-analysis of 
      observational studies addressing the risk of COVID-19 death among patients with 
      T2DM on prior DPP-4 inhibitor treatment. We pooled data from 10 observational 
      studies, showing that DPP-4 inhibitors produce a non-significant decrease in the 
      risk for COVID-19-related death. However, when administered in the inpatient 
      setting, DPP-4 inhibitors decrease the risk for COVID-19-related death by 50%. 
      Ongoing randomized controlled trials will shed further light.
FAU - Patoulias, Dimitrios
AU  - Patoulias D
AD  - Second Propedeutic Department of Internal Medicine, General Hospital 
      "Hippokration", Aristotle University of Thessaloniki, Thessaloniki, Greece.
FAU - Doumas, Michael
AU  - Doumas M
AD  - Second Propedeutic Department of Internal Medicine, General Hospital 
      "Hippokration", Aristotle University of Thessaloniki, Thessaloniki, Greece.
AD  - Veterans Affairs Medical Center, George Washington University, Washington, DC, 
      USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20210727
PL  - Korea (South)
TA  - Endocrinol Metab (Seoul)
JT  - Endocrinology and metabolism (Seoul, Korea)
JID - 101554139
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - EC 3.4.14.5 (DPP4 protein, human)
RN  - EC 3.4.14.5 (Dipeptidyl Peptidase 4)
SB  - IM
MH  - COVID-19/blood/*mortality
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/*mortality
MH  - Dipeptidyl Peptidase 4/blood
MH  - Dipeptidyl-Peptidase IV Inhibitors/pharmacology/*therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/therapeutic use
MH  - Mortality/trends
MH  - Observational Studies as Topic/*methods
MH  - *COVID-19 Drug Treatment
PMC - PMC8419608
OTO - NOTNLM
OT  - COVID-19
OT  - Diabetes mellitus, type 2
OT  - Dipeptidyl-peptidase IV inhibitors
OT  - Mortality
COIS- CONFLICTS OF INTEREST No potential conflict of interest relevant to this article 
      was reported.
EDAT- 2021/07/28 06:00
MHDA- 2021/09/15 06:00
PMCR- 2021/08/01
CRDT- 2021/07/27 03:11
PHST- 2021/03/26 00:00 [received]
PHST- 2021/06/08 00:00 [accepted]
PHST- 2021/07/28 06:00 [pubmed]
PHST- 2021/09/15 06:00 [medline]
PHST- 2021/07/27 03:11 [entrez]
PHST- 2021/08/01 00:00 [pmc-release]
AID - EnM.2021.1048 [pii]
AID - enm-2021-1048 [pii]
AID - 10.3803/EnM.2021.1048 [doi]
PST - ppublish
SO  - Endocrinol Metab (Seoul). 2021 Aug;36(4):904-908. doi: 10.3803/EnM.2021.1048. 
      Epub 2021 Jul 27.